Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 4, 2005, Pages 345-350

  Mishra, Girish ^a   Butler, Jerome ^a   Ho, Coty ^a   Melin, Susan ^a   Case, L Douglas ^a   Ennever, Peter R ^b   Magrinat, Gustav C ^b   Bearden, James D ^a   Minotto, Drew C ^a   Howerton, Russell ^a   Levine, Edward ^a   William Blackstock, A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b MOSES CONE HEALTH SYSTEM   (United States)

Author keywords

Cancer; Gemcitabine; Irinotecan; Locally advanced; Pancreatic; Radiation

Indexed keywords

CA 19-9 ANTIGEN; GEMCITABINE; HEMOGLOBIN; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASCITES; BEAM THERAPY; BILE DUCT OBSTRUCTION; BLOOD CELL COUNT; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DUODENUM OBSTRUCTION; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INFUSION; MALAISE; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; RADIATION DOSE; STOMACH OBSTRUCTION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT FAILURE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; DIARRHEA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; NAUSEA; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

EID: 23244463155     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000159559.42311.c5     Document Type: Article

References (36)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Douglass HO Jr, Stablein DM, Thomas PR. An organized multi-institutional interdisciplinary evaluation of role of radiation therapy alone or combined with chemotherapy in treatment of adenocarcinoma of the gastrointestinal tract. NCI Monogr. 1988;6:253-257.
3. Greene FL, Page DL, Fleming ID, et al. In: Haller DG, Morrow M, eds. AJCC cancer staging manual. New York, NY: Springer-Verlag; 2002.
4. Connolly MM, Dawson PJ, Michelassi F, et al. Survival in 1001 patients with carcinoma of the pancreas. Ann Surg. 1987;206:366-373.
5. Singh SM, Longmire WP Jr, Reber HA. Surgical palliation for pancreatic cancer. The UCLA experience. Ann Surg. 1990;212:132-139.
6. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer. 1981;48:1705-1710.
7. Gastrointestinal Tumor Study Group. Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer. 1985;56:2563-2568.
8. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst. 1988;80:751-755.
9. Klaassen DJ, MacIntyre JM, Catton GE, et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-an Eastern Cooperative Oncology Group study. J Clin Oncol. 1985;3:373-378.
10. Bahadori HR, Rocha Lima CM, Green MR, et al. Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res. 1999;19:5423-5428.
11. Schwartz CM, Zhan GZ, Szrajer L, et al. Evaluation of gemcitabine and irinotecan (CPT-11) as single agents and combination in solid tumors using an ex-vivo ATP assay. Proc Am Soc Clin Oncol. 2001.
12. Rocha Lima CM, Leong SS, Sherman CA, et al. Irinotecan and gemcitabine in patients with solid tumors: phase 1 trial. Oncology (Huntingt). 2002;16(suppl 5):19-24.
13. Rocha Lima CM, Savarese D, Bruckner H, et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol. 2002;20:1182-1191.
14. Fields MT, Eisbruch A, Normolle D, et al. Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine). Int J Radiat Oncol Biol Phys. 2000;47:785-791.
15. Lawrence TS, Chang EY, Hahn TM, et al. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys. 1996;34:867-872.
16. Lawrence TS, Chang EY, Hahn TM, et al. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′- difluoro-2′-deoxycytidine (gemcitabine). Clin Cancer Res. 1997;3: 777-782.
17. Shewach DS, Lawrence TS. Radiosensitization of human tumor cells by gemcitabine in vitro. Semin Oncol. 1995;22(suppl 11):68-71.
18. Shewach DS, Lawrence TS. Radiosensitization of human solid tumor cell lines with gemcitabine. Semin Oncol. 1996;23(suppl 10):65-71.
19. Martenson JA, Vigliotti AP, Pilot HC, et al. A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2003;55:1305-1310.
20. Pipas JM, Mitchell SE, Earth RJJ, et al. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 2001;50:1317-1322.
21. Yavuz AA, Aydin F, Yavuz MN, et al. Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2001;51: 974-981.
22. Blackstock AW, Bernard SA, Richards F, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol. 1999;17:2208.
23. Joensuu TK, Kiviluoto T, Karkkainen P, et al. Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004;60:444-452.
24. Blackstock AW, Tepper JE, Niedwiecki D, et al. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer. 2003;34:107-116.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
26. Rocha Lima CMS, Rotche R, Jeffery M, et al. A randomized phase 3 study comparing efficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients (pts) with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy [abstract 1005]. Proc Am Soc Clin Oncol. 2003;22:251.
27. Poen JC, Collins HL, Niederhuber JE, et al. Chemo-radiotherapy for localized pancreatic cancer: increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion 5-fluorouracil. Int J Radiat Oncol Biol Phys. 1998;40:93-99.
28. Stathopoulos GP, Rigatos SK, Dimopoulos MA, et al. Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol. 2003;14:388-394.
29. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22: 3776-3783.
30. Louvet C, Labianca R, Hammel P, et al. GemOx (gemcitabine + oxaliplatin) versus Gem (gemcitabine) in nonresectable pancreatic adenocarcinoma: final results of the GERCOR/GISCAD Intergroup Phase III [abstract 4008]. Proc Am Soc Clin Oncol. 2004;22.
31. Berlin JD, Catalane P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002;20:3270-3275.
32. Heinemann V, Quietzsch D, Gieseler F, et al. A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma. Proc Am Soc Clin Oncol. 2003;22:250.
33. O Reilly EM, Abou-Alfa GK, Letourneau R, et al. A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC) [abstract 4006]. Proc Am Soc Clin Oncol. 2004;22.
34. Richards DA, Kindler HL, Oettle H, et al. A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer [abstract 4007]. Proc Am Soc Clin Oncol. 2004;22.
35. Kindler HL, Friberg G, Stadler WM, et al. Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): updated results of a multi-center phase II trial [abstract 4009]. Proc Am Soc Clin Oncol. 2004;22.
36. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol. 2004;22:2610-2616.